Featured

September 22, 2021

CARISMA Therapeutics Announces U.S. Food and Drug Administration Grants Fast Track Designation to CT-0508 for the Treatment of Patients with Solid Tumors

PHILADELPHIA, September 22, 2021 — CARISMA Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today that that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CT-0508, a human epidermal growth factor receptor 2 (HER2) targeted chimeric antigen receptor macrophage (CAR-M) for the treatment […]

Read More

News

September 22, 2021

CARISMA Therapeutics Announces U.S. Food and Drug Administration Grants Fast Track Designation to CT-0508 for the Treatment of Patients with Solid Tumors

PHILADELPHIA, September 22, 2021 — CARISMA Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today that that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CT-0508, a human epidermal growth factor receptor 2 (HER2) targeted chimeric antigen receptor macrophage (CAR-M) for the treatment […]

Read More
May 4, 2021

CARISMA Therapeutics to Participate in Panel and Showcase Exhibit During Cellicon Valley ’21 Virtual Symposium

CARISMA’s Chief Medical Officer, Debora Barton, MD, will be participating in a panel discussion on May 6 at 2:15 pm ET entitled “Cell & Gene Startups & Innovation in Cellicon Valley” alongside other industry leaders during Cellicon Valley ’21 Virtual Symposium.” We will also showcase a virtual exhibit about CARISMA and our recent accomplishments for […]

Read More
April 28, 2021

CARISMA Therapeutics to Present Data at The American Society of Gene & Cell Therapy 24th Annual Meeting

PHILADELPHIA, April 28, 2021 — CARISMA Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced findings from two studies accepted for virtual presentation at The American Society of Gene & Cell Therapy (ASGCT) 24th Annual Meeting on Tuesday, May 11 – Friday, May 14. The findings mark the first […]

Read More
April 26, 2021

CARISMA Therapeutics Establishes Collaboration with Leading Cell Therapy Expert to Explore and Develop Allogeneic CAR-Macrophages

PHILADELPHIA, April 26, 2021 — CARISMA Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced it has established a multi-year scientific collaboration with Bruce Blazar, MD, Regents Professor of Pediatrics, Division of Blood and Marrow Transplantation and Cellular Therapy at the University of Minnesota to investigate and develop […]

Read More
April 9, 2021

CARISMA Therapeutics to Present Data at The American Association for Cancer Research Annual Meeting

PHILADELPHIA, April 9, 2021 — CARISMA Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced study findings accepted for virtual presentation at The American Association for Cancer Research (AACR) Annual Meeting on Saturday, April 10 – Thursday, April 15. The accepted data reinforces the potential of CARISMA’s proprietary chimeric […]

Read More
March 18, 2021

CARISMA Therapeutics Announces First Patient Dosed in Landmark Clinical Study Evaluating Engineered Macrophages in Humans

PHILADELPHIA, March 18, 2021 — CARISMA Therapeutics Inc., a clinical stage biopharmaceutical company spun out of the University of Pennsylvania (Penn) and focused on discovering and developing innovative immunotherapies, announced that the first patient has been dosed in the Phase 1 multi-center clinical trial for CT-0508, a human epidermal growth factor receptor 2 (HER2) targeted […]

Read More
March 11, 2021

CARISMA THERAPEUTICS TO PRESENT AT SOLEBURY CAPITAL SPRING PRIVATE COMPANY SHOWCASE

CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced that Steven Kelly, the President & CEO, will present at a virtual investor conference in March. Solebury Trout Winter Private Company Showcase March 11, 2021 Presentations can be found here. About CARISMA Therapeutics Inc. CARISMA Therapeutics Inc. is a biopharmaceutical company […]

Read More
March 1, 2021

CARISMA Therapeutics Completes Series B Financing Totaling $59 Million

PHILADELPHIA, March 1, 2021 /PRNewswire/ — CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today the second closing of its Series B equity financing, bringing the total amount raised in this round to $59 million and CARISMA’s total capital raised to date to nearly $121 million. Click here for more information.

Read More
January 7, 2021

CARISMA Therapeutics Completes Series B Funding for $47 Million to Advance Development of Novel CAR-Macrophage Immunotherapies

CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today that it has completed its Series B equity financing providing for gross proceeds of $47 million, bringing CARISMA’s total capital raised to nearly $109 million. Click here for more information.

Read More
November 24, 2020

CARISMA THERAPEUTICS TO PRESENT AT UPCOMING VIRTUAL INVESTOR CONFERENCES IN DECEMBER

CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly, the President & CEO, will present at two virtual investor conferences in December 2020. Piper Sandler 32nd Annual Virtual Healthcare Conference November 30, 2020- December 3, 2020 Presentations will be available for registered attendees via the Piper Sandler […]

Read More
November 9, 2020

CARISMA to Present New Data at The Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting

PHILADELPHIA, Nov. 9, 2020 /PRNewswire/ — CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced new preclinical findings accepted for presentation at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting (November 9 – 14, 2020). Click here for more information.

Read More
August 25, 2020

CARISMA Therapeutics Enters Into Scientific Research and Licensing Agreement With NYU Langone Health, Gains Exclusive Rights to Vpx Lentiviral Vector

PHILADELPHIA, Aug. 25, 2020 /PRNewswire/ — CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced it has entered into a scientific research and licensing agreement with Nathaniel R. Landau, PhD and NYU Langone Health through which CARISMA will attain exclusive rights to develop and commercialize their Vpx lentiviral vector globally for all indications. […]

Read More
July 27, 2020

CARISMA Therapeutics Announces FDA Clearance of IND Application for First-Ever Engineered Macrophage Immunotherapy

PHILADELPHIA, July 27, 2020 /PRNewswire/ — CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for the Company’s lead product candidate, CT-0508, an anti-human epidermal growth factor receptor 2 (HER2) targeted chimeric antigen receptor macrophage (CAR-M). […]

Read More
November 16, 2019

Carisma therapeutics announces investor conference participation

Carisma Therapeutics announced today that it will be participating in three upcoming investor conferences: Stifel 2019 Healthcare Conference, November 19-20, 2019 – Carisma’s management will deliver a presentation on Wednesday, November 20, at 4:45 pm EDT and host one-on-one meetings at the venue. The conference will be held at the Lotte New York Palace Hotel, New York, NY. Jefferies 2019 London […]

Read More
October 21, 2019

Carisma shares unique engineered macrophage cell therapy approach at the inaugural macrophage-directed therapies summit

Carisma’s VP of Business Development, Dora Mitchell, PhD and VP of Discovery Research, Michael Klichinsky, PharmD, PhD chaired and presented at the inaugural macrophage-directed therapies summit taking place October 22-24, 2019 in Boston, MA. The summit is the only platform dedicated to exploring the translation of macrophage therapies into the clinic. For full agenda and […]

Read More
September 9, 2019

Carisma Enters into a Research Collaboration with Phio Pharmaceuticals

“Metastatic solid tumors have been an intractable challenge for engineered cell therapies. Our platform technology, based on the genetically engineered macrophage, has a unique opportunity to provide benefit in this disease state,” said Dr. Michael Klichinsky, co-Founder and Vice President of Discovery at Carisma. “We are excited to work with Phio to evaluate sd-rxRNA mediated […]

Read More
June 3, 2019

Carisma Therapeutics Names Dr. Robert Petit as Chief Scientific Officer

Carisma Therapeutics is excited to welcome Robert Petit, PhD as its Chief Scientific Officer. Dr. Petit is an accomplished immuno-oncology scientist, innovator and drug developer, and a C-level executive with 25 years of experience in building and leading scientific, translational, and clinical development teams in public and private companies. View press release here.

Read More
May 9, 2019

Michael Klichinsky, VP of Discovery Research, Presents at the CAR-T and the Rise of Cellicon Valley Conference

Carisma’s Michael Klichinsky, VP of Discovery Research, joins leaders in cell therapy to present at the CAR-T and the Rise of Cellicon Valley conference to be held May 9-10, 2019 at the University of Pennsylvania (Penn). The forum is presented by Penn’s Abramson Cancer Center, the Children’s Hospital of Philadelphia and Penn’s Center for Cellular […]

Read More